Plain-English translation of NCT07655076 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage study is testing a new Dual Port Pump System—a single device that delivers insulin and measures blood sugar at the same time, instead of wearing two separate devices. Currently, people with type 1 diabetes often wear multiple devices on different parts of their body, which can be uncomfortable and complicated. Researchers want to see if combining these functions into one device can improve accuracy, reduce skin irritation, and make diabetes management simpler.
Many people with type 1 diabetes find wearing separate insulin pumps and glucose monitors burdensome and uncomfortable. Combining them into one device could reduce skin problems, device failures, and the complexity of coordinating multiple systems—but first, researchers need to make sure the glucose sensor still works accurately when placed close to the insulin infusion site.
You likely qualify if…
You likely don't qualify if…
You would stay in a hospital for either 1.5 days (Part A) or 2.5 days (Part B). During Part A, you would wear three test devices at once while researchers carefully monitor your blood sugar using lab equipment and a standard glucose monitor to see how the new device's sensor responds to insulin delivery. In Part B, you would wear the device with an automated insulin control system and eat standardized meals and do light exercise while researchers evaluate how well the system keeps your blood sugar in a safe range. Your blood sugar will be checked frequently throughout your stay.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Canada